Cerulean starts patient dosing in Phase Ib/II combination trial of CRLX101 to treat rectal cancer

US-based Cerulean Pharma has dosed its first patient in a Phase Ib/II trial of CRLX101 in combination with chemotherapy and radiation in neoadjuvant rectal cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news